Singapore • November 9–11, 2027
RADNEXUS 2027
APAC’s First Targeted Radiopharmaceuticals & Radioligand
Therapy Summit
Invitation-led participationSenior decision-maker focusCommercially relevant dialogueAPAC edition
About the summit
Where breakthrough science meets the infrastructure required to scale it.
RadNexus 2027 is a commercial forum at the intersection of nuclear medicine, targeted oncology, and global capital deployment. It connects radioligand science with the manufacturing, regulatory, supply-chain, and deal-making capabilities required to reach patients at scale.
This is not a broad academic congress. It is a focused business summit for senior leaders deploying capital, securing isotope supply, forming partnerships, and building the commercial architecture of precision radio-oncology.
Exclusive access
A curated audience of biopharma executives, investors, isotope suppliers, manufacturers, and regulators.
Actionable intelligence
Practical insight into licensing structures, isotope strategy, manufacturing scale-up, and capital allocation.
Regulatory dialogue
Cross-market perspectives spanning FDA, EMA, HSA, PMDA, TGA, and NMPA pathways.
Curated deal flow
Qualified conversations among innovators, pharma partners, strategic buyers, and active investors.
Who attends
One value chain.
One executive room.
RadNexus is designed around the people whose decisions determine whether a radiopharmaceutical programme can be funded, manufactured, approved, and commercialized.
C-suite Executives & Founders
Radiopharma biotechs and clinical-stage isotope developers.
Oncology, BD&L & M&A Leaders
Global pharmaceutical and strategic partnering teams.
Isotope Suppliers & Manufacturers
Production, enrichment, targetry, generator, and nuclear medicine infrastructure.
Specialist CDMOs & Logistics
Short-half-life manufacturing, quality, distribution, and last-mile delivery.
Investors & Corporate Venture
Venture, crossover, growth capital, private equity, and strategic investors.
Regulatory & Clinical Leaders
Policymakers, market-access experts, nuclear medicine physicians, and clinical development teams.
Summit programme
Three days. One commercial trajectory.
From science and pipeline, through manufacturing and supply, to transactions, regulation, and market access.
Day 01
The Science & Pipeline Frontier
- The Precision Oncology ShiftOpening keynote on radioligand therapy and capital deployment.
- Beyond PSMA & SSTR2The next wave of validated targets and indications.
- The Alpha-Emitter RaceActinium-225, Lead-212, and Astatine-211.
- Pipeline ShowcaseEmerging programmes presented to pharma and investors.
- Opening ReceptionExecutive networking to begin the summit.
Day 02
Manufacturing, Supply & Infrastructure
- Solving the Isotope ConstraintSupply strategy for a rapidly scaling modality.
- Short-Half-Life LogisticsProduction, distribution, and time-critical delivery.
- From Clinical to CommercialScaling manufacturing capacity and quality systems.
- Investor RoundtablesPrivate dialogue for qualified investors and company leaders.
- RadNexus Gala DinnerPremium relationship-building beyond the conference floor.
Day 03
Deals, Regulation & Market Access
- The Regulatory BridgeAligning global and APAC approval pathways.
- M&A and LicensingStructures, diligence, and lessons from major transactions.
- The Investor PerspectiveWhere specialist and crossover capital is moving next.
- Building the APAC EcosystemRegional manufacturing, regulation, and access.
- Closing ForumPriorities for the next phase of sector growth.
Programme themes are indicative and may evolve as the advisory process and faculty are confirmed.
Confirmed faculty
Announcements beginning soonSpeakers will be announced progressively.
We are curating a cross-disciplinary faculty from radiopharma biotechnology, pharmaceutical partnering, isotope manufacturing, nuclear medicine, capital markets, and regulatory bodies.
Strategic partnerships
Founding visibility in a category-defining APAC forum.
RadNexus partners gain targeted access to the executives, investors, regulators, and innovators building the radiopharmaceutical value chain. Packages emphasize credible positioning, qualified dialogue, and useful commercial interaction rather than logo volume.
Headline sponsorship
Category leadership, premium visibility, thought leadership, and the deepest executive access.
Strategic visibility
Prominent positioning, hosted engagement, showcase presence, and qualified meetings.
Ecosystem access
Focused brand visibility, delegate access, and relationship-building across the value chain.
Technology showcase
A route for emerging platforms, specialist suppliers, and enabling technologies.
Sponsorship inventory is intentionally limited.Request the prospectus or discuss a tailored partnership.
Contact partnershipsRegistration
Registration opens in November 2026.
Delegate applications will be reviewed to maintain a senior, commercially focused audience. Early registration information and pricing will be published when registration opens.
Venue
Singapore.
Venue to be announced.
The final venue, arrival, and accommodation details will be shared once confirmed.
RadNexus 2027November 9–11, 2027
Singapore
Full venue announcement forthcomingContact RadNexus
Start the right conversation.
For sponsorship, delegate, media, partnership, or general enquiries, contact the RadNexus team through Pharmasynerg Events.
sachin.sravan@synergevents.comResponse standardWithin two business days